Patient and family experience of the clinical-care pathway for teduglutide in patients with short bowel syndrome and type 3 intestinal failure

Not Applicable

Completed

• Conditions: Intestinal failure; Digestive System

• Registration Number: ISRCTN40592528
• Lead Sponsor: niversity of Manchester

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34330477/ (added 06/06/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-29
• Study Completion: 2023-03-31
• Last Update Posted: 20 June 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Diagnosed with short bowel syndrome or intestinal failure
2. Metabolically stable,
3. Apyrexial
4. Able to give informed consent
5. Can speak English
6. Stable on PN following a period of postsurgical intestinal adaption
7. Dependent on receiving PN at least twice a week
8. Able to inject themselves with Tedugutide
9. Managed by the IFU at Salford Royal NHS Trust

Exclusion Criteria

1. Under 18 years of age
2. Not suitable for Teduglutide:
2.1 Pregnant or planning conception in the next 12 months
2.2 History of malignancies within the last five years
2.3 Severe hepatic or renal impairment
3. Clinically unstable concomitant diseases: cardiovascular, respiratory, renal, infectious, endocrine, hepatic, or central nervous system.

Study & Design

• Study Type: Observational
• Study Design: Not specified